Beta Bionics Business Summary

Beta Bionics, Inc. (BBNX) is a commercial-stage medical technology company that generates revenue primarily through the sale of its flagship iLet Bionic Pancreas system and associated disposable supplies, such as insulin cartridges. The company operates through two primary business segments: the Durable Medical Equipment (DME) channel, which accounted for approximately 75% of 2025 revenue, and the rapidly expanding Pharmacy Benefit Plan (PBP) channel. For fiscal year 2026, the company has issued revenue guidance of $130 million to $135 million, driven by an installed base of over 35,000 users and a strategic shift toward pharmacy-reimbursed patient starts. In the competitive landscape of automated insulin delivery (AID), Beta Bionics competes directly with established incumbents Insulet Corporation, Tandem Diabetes Care, and Medtronic. The company distinguishes itself by offering the only autonomous "no carb counting" closed-loop algorithm, positioning it as a simplified, user-centric alternative for both Type 1 and insulin-dependent Type 2 diabetes populations. The company was founded by Dr. Edward Damiano, a professor of biomedical engineering at Boston University, alongside Firas Khatib, Toby Milgrome, and Edward and Serafina Raskin. The current leadership team is headed by President and CEO Sean Saint, a medical device veteran and former co-founder of Companion Medical, supported by CFO Stephen Feider and Chief Product Officer Mike Mensinger. Dr. Damiano remains active as Founder and Executive Chair, focusing on the development of the company’s bihormonal (insulin and glucagon) pipeline and the "Mint" tubeless patch pump. Beta Bionics is backed by a robust roster of institutional investors, including Soleus Capital, Perceptive Advisors, and Eventide Funds. Its Board of Directors, chaired by Adam Lezack, recently expanded to include Gerard Michel (CEO of Delcath Systems) to bolster its commercial scaling expertise following the company's 2025 initial public offering.